Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Susan N. Chi, MD


Neuro-Oncology

Make an Appointment

Physician

  • Deputy Director of Pediatric Neuro-Oncology
  • Senior Physician
  • Assistant Professor of Pediatrics, Harvard Medical School

Centers/Programs

Clinical Interests

  • Atypical teratoid rhabdoid tumor (ATRT)
  • Infant brain tumors
  • Neuro-oncology

Diseases Treated

  • AT/RT, Childhood
  • Brain Tumors, Childhood
  • Choroid Plexus Tumor, Childhood
  • DIPG, Childhood
  • Ependymoma, Childhood
  • Germ Cell Tumors of the Brain, Childhood
  • Glioma, Childhood
  • Medulloblastoma, Childhood

Contact Information

  • Appointments617-632-2680
  • Office Phone Number617-632-4386
  • Fax617-632-4897

Board Certification:

  • Pediatric Hematology/Oncology

Fellowship:

  • Memorial Sloan Kettering Cancer Center
  • New York University Medical Center

Residency:

  • Yale New Haven Children's Hospital, Pediatrics

Medical School:

  • Mount Sinai School of Medicine

Research

Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Pediatr Blood Cancer. 2021 Apr 12; e29031.
View in: PubMed

Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Mar 09.
View in: PubMed

Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 Feb 09; e28930.
View in: PubMed

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. J Clin Invest. 2020 12 01; 130(12):6325-6337.
View in: PubMed

A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 02; 68(2):e28787.
View in: PubMed

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020 10 14; 22(10):1527-1535.
View in: PubMed

A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa120.
View in: PubMed

Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262.
View in: PubMed

Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro Oncol. 2020 07 07; 22(7):944-954.
View in: PubMed

Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020 Aug; 149(1):113-122.
View in: PubMed

Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
View in: PubMed

Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890.
View in: PubMed

Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355.
View in: PubMed

Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. J Clin Oncol. 2019 12 10; 37(35):3335-3339.
View in: PubMed

Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neurooncol Pract. 2020 Jan; 7(1):4-10.
View in: PubMed

Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
View in: PubMed

A Central Role of Radiation Therapy in Central Nervous System Germinoma. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):970-971.
View in: PubMed

Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019 03 18; 21(4):537-546.
View in: PubMed

Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
View in: PubMed

Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study. Pediatr Blood Cancer. 2019 06; 66(6):e27682.
View in: PubMed

Improvement of hereditary palmoplantar keratoderma with oral trametinib. Pediatr Dermatol. 2019 Jan; 36(1):e48-e49.
View in: PubMed

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555.
View in: PubMed

A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018 09; 65(9):e27217.
View in: PubMed

Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211.
View in: PubMed

Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996.
View in: PubMed

A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. Pediatr Blood Cancer. 2017 Nov; 64(11).
View in: PubMed

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017 May 15; 23(10):2433-2441.
View in: PubMed

Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. J Neurooncol. 2017 05; 133(1):119-128.
View in: PubMed

Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
View in: PubMed

Pediatric malignant germ cell tumors: A comparison of the neuro-oncology and solid tumor experience. Pediatr Blood Cancer. 2016 12; 63(12):2086-2095.
View in: PubMed

Central Versus Extraventricular Neurocytoma in Children: A Clinicopathologic Comparison and Review of the Literature. J Pediatr Hematol Oncol. 2016 08; 38(6):479-85.
View in: PubMed

Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. Pediatr Blood Cancer. 2016 09; 63(9):1527-34.
View in: PubMed

Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302.
View in: PubMed

Building a new process: Nursing verification of pediatric oral chemotherapy. J Clin Oncol. 2016 Mar; 34(7_suppl):199.
View in: PubMed

Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. Neuro Oncol. 2016 06; 18(6):764-78.
View in: PubMed

Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174.
View in: PubMed

Classification of treatment-related mortality in children with cancer: a systematic assessment. Lancet Oncol. 2015 Dec; 16(16):e604-10.
View in: PubMed

A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45.
View in: PubMed

Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013. Cancer Genet. 2014 Sep; 207(9):346-51.
View in: PubMed

Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr. 2014 Oct; 14(4):356-64.
View in: PubMed

Phase I individual dose titration trial of the human corticotropin-releasing factor (hcrf), corticorelin acetate injection (xerecept) in pediatric patients with peritumoral edema of the brain. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii23.
View in: PubMed

Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9.
View in: PubMed

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014 Apr; 61(4):636-42.
View in: PubMed

Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013 Oct; 60(10):1630-5.
View in: PubMed

Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol Oncol. 2013 Jun; 7(3):497-512.
View in: PubMed

Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer. 2012 Dec 15; 59(7):1155-7.
View in: PubMed

Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9.
View in: PubMed

Brain tumors in children. Curr Probl Pediatr Adolesc Health Care. 2012 Apr; 42(4):80-103.
View in: PubMed

Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011 Oct 20; 29(30):3999-4006.
View in: PubMed

Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer. 2010 Oct 01; 116(19):4632-7.
View in: PubMed

Germinoma with malignant transformation to nongerminomatous germ cell tumor. J Neurosurg Pediatr. 2010 Sep; 6(3):295-8.
View in: PubMed

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010 Jun 20; 28(18):3069-75.
View in: PubMed

Biological modification strategies following marrow ablative, high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue (AHSCR) for pediatric brain tumors. Pediatr Blood Cancer. 2010 Apr; 54(4):654-6.
View in: PubMed

Introduction to a special issue on pediatric neuro-oncology. J Child Neurol. 2009 Nov; 24(11):1341-2.
View in: PubMed

Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. Pediatr Blood Cancer. 2009 Sep; 53(3):417-23.
View in: PubMed

A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatr Blood Cancer. 2009 Sep; 53(3):343-7.
View in: PubMed

Pediatric Neuro-Oncology: Back to the Basics. 2009.

Tumors of the Brain and Spinal Cord. Oncology of Infancy and Childhood (Orkin, Fisher, Look, Lux, Ginsbrug, Nathan, eds). 2009; 601-720.

Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009 Jan 20; 27(3):385-9.
View in: PubMed

Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. J Neuropathol Exp Neurol. 2008 Sep; 67(9):911-20.
View in: PubMed

Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. J Neurooncol. 2008 Aug; 89(1):89-95.
View in: PubMed

Results from a single-arm, multi-institutional Phase II study Of multi-agent intrathecal and systemic Cchemotherapy with age- and risk-adapted radiation therapy for children with newly diagnosed CNS Atypical Teratoid/Rhabdoid Tumor. Neuro-oncol. 2008; 10(3):373.

Long-term medical, psychologicak and educational isues in pediatric low-grade gliomas treated with surgery only. Neuro-Oncol. 2007.

Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007 Jul; 49(1):34-40.
View in: PubMed

Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8.
View in: PubMed

Supratentorial primitive neuroectodermal tumors: Final outcome for children enrolled on Head Start I and II. Neuro-Oncol. 2007; 9:192.

Does histologic grade correlate with clinical outcome in pediatric intracranial ependymoma?. Neuro-Oncol. 2007; 9:217.

Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: a final update on “Head Start” induction chemotherapy intensified with high-dose methotrexate. Proceedings of ASCO. 2007.

Pineoblastoma in the pediatric population: Review of a single institution’s experience. Neuro-Oncol. 2007; 9:201.

Glomerular filtration rate in comparison to serum creatinine and audiologic results in predicting toxicity in pediatric patients receiving vincristine and carboplatin. Neuro-Oncol. 2007; 9:175.

Oligodendroglial lineage marker expression in ependymal tumors. Neuro-Oncol. 2007; 9:218.

Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007 Mar; 82(1):95-101.
View in: PubMed

Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5.
View in: PubMed

A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005 Nov; 27(11):573-81.
View in: PubMed

Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol. 2005 Mar; 72(1):77-84.
View in: PubMed

Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004 Dec 15; 22(24):4881-7.
View in: PubMed

The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2004 Jan; 42(1):46-51.
View in: PubMed

Pediatric Neuro-Oncology Program Fellows Manual. 2004.

Expression of SSX-2 and SSX-4 genes in neuroblastoma. Int J Biol Markers. 2002 Oct-Dec; 17(4):219-23.
View in: PubMed

Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res. 2001 Sep 15; 61(18):6892-8.
View in: PubMed

Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):632-4.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top